Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer Soria, J., Sequist, L. V., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Yu, H. A., Solomon, B. J., Ou, S. H., Papadimitrakopoulou, V., Oxnard, G. R., Horn, L., Dziadziuszko, R., Chao, B., Spira, A. I., Liu, S., Mekhail, T., Matheny, S., Litten, J., Camidge, R. D. ELSEVIER SCI LTD. 2014: 199

View details for DOI 10.1016/S0959-8049(14)70731-2

View details for Web of Science ID 000347755700606